The emergence of AI and biosensors offers a chance to address inefficiencies in drug development.

Basket and umbrella studies as well as adaptive enrichment design strategies represent novel approaches to testing targeted therapeutics in oncology, and a session at ASCO's annual meeting discussed ...

Health care is undergoing an important and well-needed shift from a one-size-fits-all approach to more personalized, precise, patient-focused care. A similar approach needs to be implemented at scale ...

In today’s ACT Brief, we cover how AI is being deployed to optimize global trial design, why ESG performance is emerging as a core vendor qualification signal, and how sites are becoming more ...

The traditional randomised controlled trial (RCT) model has been used for decades in drug development. Although it is considered the gold standard of trial designs, sponsors are increasingly using ...

The evolution of clinical trials shows that although much has changed, several things remain the same. When a patient expresses interest in a trial, they complete an informed consent process, and ...

The aim of this article was to design clinical trials that test treatments for clinical significance in individual patients. In a repeated measures design a scalar summary statistic describes the ...

Raja Shankar, VP of machine learning at IQVIA, discusses which AI capabilities sponsors are most likely to adopt first to ...

The Forum on Regenerative Medicine hosted its fourth public workshop with the goal of exploring the design complexities and ethical issues associated with clinical trials for gene-based therapies.

Systematic Review of the Diagnosis and Management of Malignant Extradural Spinal Cord Compression: The Cancer Care Ontario Practice Guidelines Initiative‘s Neuro-Oncology Disease Site Group Current ...